-
Correction to Lancet Diabetes Endocrinol 2022; 10: 407–17 Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-22
Abstract not available
-
Banning junk food ads: commitment waning in the UK? Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-22 Talha Burki
Abstract not available
-
Diagnosis of thyroid nodules Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-22 Erik K Alexander, Edmund S Cibas
Thyroid nodules are common, usually asymptomatic, and often pose minimal risk to the affected patient. However, 10–15% prove malignant and serve as the rationale for diagnostic assessment. Safely identifying and treating a relevant thyroid cancer through a cost-effective process is the primary goal of the treating practitioner. Ultrasound is the principal means of initial nodule assessment and should
-
Management of thyroid nodules Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-22 Erik K Alexander, Gerard M Doherty, Justine A Barletta
In the past 30 years, there has been a substantial rise in the detection of thyroid nodules. Largely asymptomatic, thyroid nodules are most often incidental findings that typically pose minimal risk. Data supporting these findings show a rapid rise in the incidental detection of thyroid nodules and cancer, but minimal effect on mortality rates, despite treatment. These data imply that historical approaches
-
Type 1 diabetes in diverse ancestries and the use of genetic risk scores Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-17 Maria J Redondo, Christopher R Gignoux, Dana Dabelea, William A Hagopian, Suna Onengut-Gumuscu, Richard A Oram, Stephen S Rich
Over 75 genetic loci within and outside of the HLA region influence type 1 diabetes risk. Genetic risk scores (GRS), which facilitate the integration of complex genetic information, have been developed in type 1 diabetes and incorporated into models and algorithms for classification, prognosis, and prediction of disease and response to preventive and therapeutic interventions. However, the development
-
Prioritising COVID-19 over everything: the unintended harm Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-09 The Lancet Diabetes & Endocrinology
Abstract not available
-
Diabetes in humanitarian crises Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-01 Talha Burki
Abstract not available
-
Europe's obesity burden on the rise: WHO report Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-01 Vijay Shankar Balakrishnan
Abstract not available
-
Cross-sectional associations between the gut microbe Ruminococcus gnavus and features of the metabolic syndrome Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-01 Louise Grahnemo, Maria Nethander, Eivind Coward, Maiken Elvestad Gabrielsen, Satya Sree, Jean-Marc Billod, Lars Engstrand, Sanna Abrahamsson, Arnulf Langhammer, Kristian Hveem, Claes Ohlsson
Abstract not available
-
How should endocrinologists diagnose and treat non-alcoholic fatty liver disease? Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-06-01 Christopher D Byrne, Giovanni Targher
Abstract not available
-
The effect of COVID-19 on routine diabetes care and mortality in people with diabetes. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-27 David Hopkins,Francesco Rubino
-
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-27 Jonathan Valabhji,Emma Barron,Tessa Gorton,Chirag Bakhai,Partha Kar,Bob Young,Kamlesh Khunti,Naomi Holman,Naveed Sattar,Nicholas J Wareham
BACKGROUND The Office for Health Improvement and Disparities, part of the UK Government Department of Health and Social Care, highlighted an emerging signal of increased non-COVID-19-related deaths in England between July and October, 2021, with a potentially disproportionate higher increase in people with diabetes. We aimed to substantiate and quantify this apparent excess mortality, and to investigate
-
Treating diabetes: combining tradition and science Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-27 Manjulika Das
Abstract not available
-
Sylvia Kehlenbrink: facing the extremes Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-26 Carl Power
Abstract not available
-
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-18 Olivier Chabre, Marie Muller, Justine Cristante, Jean-Luc Cracowski, Emmanuel Gay
Abstract not available
-
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence – Authors' reply Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-18 Maria Fleseriu, Frederic Castinetti, Mônica Gadelha, Andrea Giustina, André Lacroix, Shlomo Melmed, John Newell-Price, Rosario Pivonello, Martin Reincke, Beverly M K Biller
Abstract not available
-
The current state of clinical islet transplantation Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-16 Rainer W G Gruessner
Abstract not available
-
Pancreatic islet transplantation in type 1 diabetes: 20-year experience from a single-centre cohort in Canada Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-16 Braulio A Marfil-Garza, Sharleen Imes, Kevin Verhoeff, Joshua Hefler, Anna Lam, Khaled Dajani, Blaire Anderson, Doug O'Gorman, Tatsuya Kin, David Bigam, Peter A Senior, A M James Shapiro
Background Islet transplantation offers an effective treatment for selected people with type 1 diabetes and intractable hypoglycaemia. Long-term experience, however, remains limited. We report outcomes from a single-centre cohort up to 20 years after islet transplantation. Methods This cohort study included patients older than 18 years with type 1 diabetes undergoing allogeneic islet transplantation
-
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-13 Ann V Schwartz, Jye-Yu C Backlund, Ian H de Boer, Mishaela R Rubin, Annette Barnie, Kaleigh Farrell, Victoria R Trapani, Naina Sinha Gregory, Amisha Wallia, Ionut Bebu, John M Lachin, Barbara H Braffett, Rose Gubitosi-Klug
Background Type 1 diabetes is associated with lower bone mineral density (BMD) and increased fracture risk, but little is known regarding the effects of diabetes-related factors on BMD. We assessed whether these factors are associated with lower hip BMD among older adults with type 1 diabetes. Methods This cross-sectional study was embedded in a long-term observational study, the Epidemiology of Diabetes
-
Bone fragility in type 1 diabetes: new insights and future steps Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-13 Nicola Napoli, Caterina Conte
Abstract not available
-
Is autonomous cortisol secretion sexually dimorphic? Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-06 Riccardo Pofi, Jeremy W Tomlinson
Abstract not available
-
Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-06 Timo Deutschbein, Giuseppe Reimondo, Guido Di Dalmazi, Irina Bancos, Jekaterina Patrova, Dimitra Argyro Vassiliadi, Anja Barač Nekić, Miguel Debono, Pina Lardo, Filippo Ceccato, Luigi Petramala, Alessandro Prete, Iacopo Chiodini, Miomira Ivović, Kalliopi Pazaitou-Panayiotou, Krystallenia I Alexandraki, Felicia Alexandra Hanzu, Paola Loli, Martin Fassnacht
Background The association between cortisol secretion and mortality in patients with adrenal incidentalomas is controversial. We aimed to assess all-cause mortality, prevalence of comorbidities, and occurrence of cardiovascular events in uniformly stratified patients with adrenal incidentalomas and cortisol autonomy (defined as non-suppressible serum cortisol on dexamethasone suppression testing).
-
Management of menopause: a view towards prevention Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-05 Roger A Lobo, Anne Gompel
Women spend approximately one-third of their lives with menopause, which occurs around 50 years of age. It is now appreciated that several important metabolic and cardiovascular disease risks emerge during the menopausal transition. Many important conditions occur 10–15 years after menopause, including weight gain and obesity, metabolic syndrome, diabetes, osteoporosis, arthritis, cardiovascular disease
-
Menopause: a turning point for women's health Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-05 The Lancet Diabetes & Endocrinology
Abstract not available
-
Hot topics on insulin access: the issue of thermostability Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-04 Talha Burki
Abstract not available
-
Menopause: a cardiometabolic transition Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-05-04 Rossella E Nappi, Peter Chedraui, Irene Lambrinoudaki, Tommaso Simoncini
Menopause is often a turning point for women's health worldwide. Increasing knowledge from experimental data and clinical studies indicates that cardiometabolic changes can manifest at the menopausal transition, superimposing the effect of ageing onto the risk of cardiovascular disease. The menopausal transition is associated with an increase in fat mass (predominantly in the truncal region), an increase
-
Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0–14 years: a population-based retrospective cohort study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-27 Fanny Jansson Sigfrids, Per-Henrik Groop, Valma Harjutsalo
Background The incidence and temporal trends of moderate and severe albuminuria during recent decades are poorly described in type 1 diabetes. We aimed to assess diabetes duration-specific incidence rates, cumulative incidence, and secular trends of albuminuria in type 1 diabetes in Finland. Methods We conducted a population-based, retrospective cohort study of a stratified random sample (n=1500) of
-
The uncomfortable truth about kidney disease in type 1 diabetes Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-27 Bruce A Perkins
Abstract not available
-
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-26 Furio Pacini
Abstract not available
-
Singapore's “War on Diabetes” Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-25 Yong Mong Bee, E Shyong Tai, Tien Y Wong
Abstract not available
-
Methodological considerations in D-health cancer mortality results Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-21 Sam Egger, David P Smith, Visalini Nair-Shalliker
Abstract not available
-
Methodological considerations in D-health cancer mortality results – Authors' reply Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-21 Rachel E Neale, Briony Duarte Romero, Donald S A McLeod, Dallas R English, Gunter Hartel, Jolieke C van der Pols, Alison J Venn, Penelope M Webb, David C Whiteman, Mary Waterhouse
Abstract not available
-
Tirzepatide adds hepatoprotection to its armoury Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 Giovanni Targher
Abstract not available
-
Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 Amalia Gastaldelli, Kenneth Cusi, Laura Fernández Landó, Ross Bray, Bram Brouwers, Ángel Rodríguez
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 receptor agonist under development for the treatment of type 2 diabetes. The aim of this substudy was to characterise the changes in liver fat content (LFC), volume of visceral adipose tissue (VAT), and abdominal subcutaneous adipose tissue (ASAT) in response to tirzepatide or insulin
-
Add-on value of tirzepatide versus semaglutide Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 André J Scheen
Abstract not available
-
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 Tim Heise, Andrea Mari, J Hans DeVries, Shweta Urva, Jing Li, Edward John Pratt, Tamer Coskun, Melissa K Thomas, Kieren J Mather, Axel Haupt, Zvonko Milicevic
Background Tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, shows a remarkable ability to lower blood glucose, enabling many patients with long-standing type 2 diabetes to achieve normoglycaemia. We aimed to understand the physiological mechanisms underlying the action of tirzepatide in type 2 diabetes. Methods This multicentre, randomised, double-blind
-
SURPASSing the current dogma: is our framework shifting? Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 Natasha P Malkani, Vanita R Aroda
Abstract not available
-
Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-22 Tadej Battelino, Richard M Bergenstal, Angel Rodríguez, Laura Fernández Landó, Ross Bray, Zhentao Tong, Katelyn Brown
Background Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist under development for the treatment of type 2 diabetes. In this study, we used continuous glucose monitoring (CGM) to compare the 24 h glucose profile for participants given tirzepatide compared with those given insulin degludec. Methods This substudy of the open-label, parallel-group
-
The ABC targets of diabetes in India Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-21 Jennifer Manne-Goehler
Abstract not available
-
Decision making in differences of sex development/intersex care in the USA: bridging advocacy and family-centred care Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-21 David E Sandberg, Eric Vilain
Abstract not available
-
Achievement of guideline recommended diabetes treatment targets and health habits in people with self-reported diabetes in India (ICMR-INDIAB-13): a national cross-sectional study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-21 Ranjit Mohan Anjana, Ranjit Unnikrishnan, Mohan Deepa, Ulagamathesan Venkatesan, Rajendra Pradeepa, Shashank Joshi, Banshi Saboo, Ashok Kumar Das, Sarita Bajaj, Anil Bhansali, Sri Venkata Madhu, Vinay Kumar Dhandhania, Puthiyaveettil Kottayam Jabbar, Sunil M Jain, Arvind Gupta, Subhankar Chowdhury, Mohammed K Ali, Elangovan Nirmal, Viswanathan Mohan
Background There is little information on comprehensive diabetes care comprising glycaemic, lipid, and blood pressure control in India; therefore, we aimed to assess the achievement of treatment targets among adults with self-reported diabetes. Methods The Indian Council of Medical Research (ICMR)-India Diabetes (INDIAB) study is a cross-sectional, population-based survey of adults aged 20 years or
-
Long COVID: the elephant in the room Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-07 The Lancet Diabetes & Endocrinology
Abstract not available
-
War in Ukraine ups demand for iodine pills Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-05 Talha Burki
Abstract not available
-
Global thyroid estimates in 2020 Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 Livia Lamartina,Sophie Leboulleux,Isabelle Borget,Martin Schlumberger
-
Targeting PCSK9 inhibitors to those who will benefit most Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 Traci A Turner, Evan A Stein
Abstract not available
-
Dapagliflozin in young people with type 2 diabetes Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 Kalie L Tommerdahl, Robert G Nelson, Petter Bjornstad
Abstract not available
-
Breakthrough technology for in-hospital glucose monitoring Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 David Kerr, David Klonoff
Abstract not available
-
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trial Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 Petr Ostadal, Philippe Gabriel Steg, Yann Poulouin, Deepak L Bhatt, Vera A Bittner, Terrence Chua, Rafael Diaz, Shaun G Goodman, Yong Huo, Johan Wouter Jukema, Yuri Karpov, Robert Pordy, Michel Scemama, Michael Szarek, Harvey D White, Gregory G Schwartz
Background Many patients with acute coronary syndrome have concurrent metabolic risk factors that affect risk of major adverse cardiovascular events (MACE). We aimed to assess the effects of the PCSK9 inhibitor alirocumab compared with placebo on MACE according to baseline metabolic risk factors. Methods We performed a post-hoc analysis of the ODYSSEY OUTCOMES trial, which was a multicentre, double-blind
-
Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 William V Tamborlane, Lori M Laffel, Naim Shehadeh, Elvira Isganaitis, Michelle Van Name, Jayantha Ratnayake, Cecilia Karlsson, Ensio Norjavaara
Background Since there are few treatment options for young people with type 2 diabetes, we aimed to assess the efficacy and safety of dapagliflozin as add-on therapy in children, adolescents, and young adults with type 2 diabetes receiving metformin, insulin, or both. Methods This multicentre, placebo-controlled, double-blind, randomised phase 3 study was undertaken at 30 centres in five countries
-
Diabetes in Pakistan: addressing the crisis Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-28 Zulfiqar A Bhutta, Zia Ul Haq, Abdul Basit
Abstract not available
-
Data processing in the DMagic cluster randomised controlled trial. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-04-01 Edward Fottrell,Carina King,Kishwar Azad,
-
Caring for people with diabetes and non-communicable diseases in Ukraine: a humanitarian emergency Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-25 Galyna Maystruk, Sigiriya Aebischer Perone, Valentyna Anufriyeva, Philippa Boulle, François Chappuis, Bruno Lab, David Beran
Abstract not available
-
Rising diabetes diagnosis in long COVID Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-21 K M Venkat Narayan, Lisa R Staimez
Abstract not available
-
Risks and burdens of incident diabetes in long COVID: a cohort study Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-21 Yan Xie, Ziyad Al-Aly
Background There is growing evidence suggesting that beyond the acute phase of SARS-CoV-2 infection, people with COVID-19 could experience a wide range of post-acute sequelae, including diabetes. However, the risks and burdens of diabetes in the post-acute phase of the disease have not yet been comprehensively characterised. To address this knowledge gap, we aimed to examine the post-acute risk and
-
Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-14 Tim I M Korevaar, Rima Dhillon-Smith
Abstract not available
-
Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-14 Myrthe M van Dijk, Rosa Vissenberg, Eric Fliers, Joris A M van der Post, Marie-Louise P van der Hoorn, Sabina de Weerd, Walter K Kuchenbecker, Annemieke Hoek, J Marko Sikkema, Harold R Verhoeve, Kimiko A Broeze, Corry H de Koning, Willem Verpoest, Ole B Christiansen, Carolien Koks, Jan P de Bruin, Dimitri N M Papatsonis, Helen Torrance, Mariëtte Goddijn
Background Women positive for thyroid peroxidase antibodies (TPO-Ab) have a higher risk of recurrent pregnancy loss. Evidence on whether levothyroxine treatment improves pregnancy outcomes in women who are TPO-Ab positive women with recurrent pregnancy loss is scarce. The aim of this study was to determine if levothyroxine increases live birth rates in women who were TPO-Ab positive with recurrent
-
Ukraine: diabetes on the front line. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-09 The Lancet Diabetes Endocrinology
-
Thank you to The Lancet Diabetes & Endocrinology clinical and statistical peer reviewers in 2021. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-08 The Lancet Diabetes Endocrinology Editors
-
Women in diabetes research: stepping towards equity. Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-07 Linda A DiMeglio,Jamie R Wood,Eda Cengiz
-
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020 Lancet Diabetes Endocrinol. (IF 32.069) Pub Date : 2022-03-07 Margherita Pizzato, Mengmeng Li, Jerome Vignat, Mathieu Laversanne, Deependra Singh, Carlo La Vecchia, Salvatore Vaccarella
Background Thyroid cancer incidence rates have increased in many countries and settings; however, mortality rates have remained stable at lower rates. This epidemiological pattern has been largely attributed to an overdiagnosis effect. Timely evidence for the global epidemiological status is necessary to identify the magnitude of this problem and the areas mostly affected by it. We therefore aimed